miRNA-325-3p overexpression mitigates partial bladder outlet obstruction (PBOO) by regulating the TLR4/NF-κB(p65) pathway

Type
Research paper

Keywords
miRNA-325-3p, ILK, PBOO, BSMC, TLR4, NF-κB(p65)

Abstract
Introduction
The microRNA (miRNA) is a noncoding RNA that plays an important role in many diseases. Partial bladder outlet obstruction (PBOO) is a blockage between the outlet of the neck of the bladder and the external urethral orifice secondary to prostate hyperplasia and urethral stricture, and causative of morphological and functional abnormalities in the bladder. We examine the effects of miRNA-325-3p on PBOO and related mechanisms through an in-vitro study.

Material and methods
Primary BSMCs were extracted from SD rats and subjected to TGF-β1 stimulation to form a cell model of PBOO. Cell proliferation was measured by CCK-8 assay, and the gene and protein expressions were measured by RT-qPCR, western blot, and immunofluorescence. The correlation between miRNA-325-3p and ILK was analyzed through a double-luciferase target experiment.

Results
The proliferation of BSMCs in the model group increased more significantly than in the normal group (P<0.001) with miRNA-325-3p repression, and led to the activation of ILK and the TLR4/NF-κB(p65) pathway as well as significant changes in the marker proteins. With miRNA-325-3p transfection, the rate of cell proliferation of the miRNA-325-3p group was significantly suppressed with ILK repression compared with that of the model group, and led to the suppression of TLR4/NF-κB(p65) activity and the regulation of protein expressions. However, the miRNA-325-3p treatment’s effects disappeared as ILK was supplemented. The double-luciferase experiment helped miRNA-325-3p target ILK in BSMCs.

Conclusions
miRNA-325-3p overexpression may play a key role in PBOO-induced cell proliferation by targeting ILK and suppressing the TLR4/NF-κB(p65) signaling pathway.
miRNA-325-3p overexpression mitigates partial bladder outlet obstruction (PBOO) by regulating the TLR4/NF-κB(p65) pathway

Zhaofei Liu¹,#, Yiduo Zhou²,#, Ziyang Liu³,#, Yi Huang⁴, Jie Gao², Le Shu², Ye He⁴, Sicong Zhang², Zhengsen Chen², Baixin Shen², Zhongqing Wei², Liucheng Ding²,*

1. Department of Urology, Affiliated Lianyungang Hospital of Nanjing University of Chinese Medicine, Lianyungang, 222000, China
2. Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, China
3. Major in Clinical Medicine, Nanjing Medical University, Nanjing, 210000, China
4. Department of Urology, Jiangnan University Affiliated Hospital, Wuxi, 214000, China

# Equal contribution to this research
* Corresponding author

Running head: Effects of miRNA-325-3p on PBOO

This study was supported by National Natural Science Foundation of China (No. 81300572), the Natural Science Foundation of Jiangsu Province (Nos. BK 20181093 and BK2011860), the Medical Science Fund for Young Scholars of Jiangsu Province (No. QNRC2016676), and the Medical Research Program of Jiangsu Commission of Health (No. M2020086).

Abstract
Introduction: The microRNA (miRNA) is a noncoding RNA that plays an important role in many diseases. Partial bladder outlet obstruction (PBOO) is a blockage between the outlet of the neck of the bladder and the external urethral orifice secondary to prostate hyperplasia and urethral stricture, and causative of morphological and functional abnormalities in the bladder. We examine the effects of miRNA-325-3p on PBOO and related mechanisms through an in-vitro study.

Materials and methods: Primary BSMCs were extracted from SD rats and subjected to TGF-β1 stimulation to form a cell model of PBOO. Cell proliferation was measured by CCK-8 assay, and the gene and protein expressions were measured by RT-qPCR, western blot, and immunofluorescence. The correlation between miRNA-325-3p and ILK was analyzed through a double-luciferase target experiment.

Results: The proliferation of BSMCs in the model group increased more significantly than in the normal group (P<0.001) with miRNA-325-3p repression, and led to the activation of ILK and the TLR4/NF-κB(p65) pathway as well as significant changes in the marker proteins. With miRNA-325-3p transfection, the rate of cell proliferation of the miRNA-325-3p group was significantly suppressed with ILK repression compared with that of the model group, and led to the suppression of TLR4/NF-κB(p65) activity and the regulation of protein expressions. However, the miRNA-325-3p treatment’s effects disappeared as ILK was supplemented. The double-luciferase experiment helped miRNA-325-3p target ILK in BSMCs.

Conclusion: miRNA-325-3p overexpression may play a key role in PBOO-induced cell proliferation by targeting ILK and suppressing the TLR4/NF-κB(p65) signaling
Introduction

Partial bladder outlet obstruction (PBOO) is a blockage between the neck of the outlet of the bladder and the external urethral orifice that is secondary to prostate hyperplasia and urethral stricture as well as causative of morphological and functional abnormalities in the bladder [1]. Conventional treatment aims at clearing the urinary obstruction through medical and surgical approaches, which in most cases attain the goal of treatment without improving lower urinary tract symptoms (LUTS). Evolving interest in exploring bladder dysfunction in the context of PBOO suggests a shift in emphasis in research from obstruction removal. LUTS are considered to be more closely associated with pathological changes secondary to PBOO than with the condition itself, and this highlights the significance of appropriately understanding the potential mechanism of PBOO-induced morphological and functional changes in the bladder smooth muscle and the relevant biological processes at the molecular level [2].

PBOO-induced abnormal proliferation of the bladder smooth muscle cells (BSMCs) is considered to be a major contributor to faltering recovery of the bladder pathway.

Keywords: miRNA-325-3p; ILK; PBOO; BSMC; TLR4; NF-κB(p65)
function [3]. Studies have shown that in case of bladder impairment, the phenotypic plasticity of BSMCs is a key player in the development and progression of human diseases [4, 5]. However, little is known about the molecular mechanism of phenotypic plasticity in BSMCs. A variety of signaling molecules, such as PDGF-PDGF-BB, TGF-β, and ECM, as well as environmental factors, like ischemia, hypoxia, vesical pressure, and mechanical stretch, are known to have regulatory effects on BSMCs in terms of phenotypic plasticity and proliferation [5].

MicroRNAs (miRNAs) are a class of small, single-stranded non-coding RNAs that affect such physiological and pathological processes as cell proliferation, mutation, and apoptosis as post-transcriptional regulators of the target gene expression through translational repression and mRNA decay by imperfectly binding to their target mRNAs at the 3’UTR or 5’UTR [6]. Imperfect base pairing is involved in this mechanism, and makes it possible to efficiently predict the miRNA target. Regulatory effects based on the imperfect nature of binding and base pairing imply the formation of a wide and intricate network to regulate gene expression mediated by miRNAs. In spite of the subtle differences in their expression, it has been suggested that miRNAs play a critical role in a wide range of physiological and pathological processes [6]. Variations in the profiles of MiRNA expressions have been observed at different time points after the onset of PBOO. Ekman et al. [7] discovered low expression of miRNA-29c in case of PBOO. The miRNA-29 family is known to have strong anti-fibrotic effects that can help mediate the expression of over 50 target extracellular matrix (ECM) genes, such as mRNA expressions of types-I and -III
collagens, and elastin. Increased TGF-β1 expression has been detected in case of PBOO [8]. The authors of [9] reported that members of the miRNA-29 family [7], and miRNA-132/212 [10], miRNA-133, and miRNA-101 [11] are expressed in PBOO.

Gheinani [12] and Gheinani [13] demonstrated a significant increase in miRNA-21 expression in models of rats and mice with PBOO. This indicates that the pathogenesis of PBOO may involve the abnormal expression of miRNAs. Abnormalities in miR-325-3p expression are reported to be strongly correlated with renal fibrosis [14].

Materials and Method

Materials

The following experimental materials were used in this study: integrin-linked kinase (ILK) (KeyGen Biotech, China, #KGYT2346-7), TRIzol reagent (Invitrogen, USA, #15596-026), PrimeScript™ RT master mix (Takara, Japan, #RR036B), and One Step TB Green™ PrimeScript™ RT-PCR Kit II (SYBR Green) (TaKaRa, Japan, #RR086B).

Isolation of primary BSMCs of rat

Once they had been anesthetized, the bladder detrusor muscle layer was removed from each adult rat. This was followed by removal of the uroepithelium, lamina propria, serous membrane, and fat tissue. The detrusor smooth muscle tissue was obtained, cut into three fragments each with a diameter of 1 mm, and digested in
trypsin/EDTA for 30 min at 37 °C. The fragments were then minced into smaller pieces by using scissors and placed onto a thermostatic shaking table for further digestion in 0.1% collagenase I for 30 min at 37 °C. The resulting suspension was filtered through a 200-mesh cell strainer and centrifuged to collect cells from the filtrate. The cell pellet was washed twice with PBS and resuspended in DMEM/F12 containing 10% FBS. The culture medium was replaced with a fresh medium every 3 or 4 days.

Immunofluorescence (IF) staining

The cell samples (smears or slides) were air-dried and placed in a 4% paraformaldehyde (PFA) solution for overnight. They were then permeabilized and rinsed three times (3 min each) with PBS. Each section was treated with two drops of a methanol solution with 3% H₂O₂ and blocked for 10 min at room temperature (15 °C –25 °C) before being rinsed with PBS three times. Following the addition of 100 μL of normal goat serum (ready to use) and incubation for 20 min at room temperature, each section was incubated with 50 μL of primary antibody (diluted at 1:100) in a humid incubator for 2 h at 37 °C. Then, the cells were rinsed three times with PBS, incubated with 50 μL of FITC (diluted at 1:100) for 1 h in a dark environment at 37 °C, and then rinsed three times once again with PBS. Following this, the cells were counterstained. After mounting them, protein expression in the cells was observed through a microscope and three high-expression areas were photographed.
Real-time qf-PCR

Total RNAs were extracted from the smooth muscle tissues or SMCs using the TRIzol reagent. The PrimeScript™ RT master mix was used for reverse transcription to obtain cDNA for amplification. The primer sequences were as shown in Table 1. Real-time qf-PCR was performed to determine the relative levels of expressions of the relevant mRNAs with the $2^{-\Delta\Delta CT}$ method.

Cell transfection

The primary BSMCs were transfected after passage twice. The MiR-325-3p and LV-ILK used had both been designed, constructed, and transfected by Nanjing KeyGen Biotech Co., Ltd.

Western blot (WB) test

The smooth muscle tissues or SMCs were added to a 1 mL lysis buffer and placed on a shaking table at 4 °C for gentle oscillation for 15 min, followed by centrifugation at 14000 rpm for 15 min at 4 °C. The isolated supernatant was collected for the quantitative determination of total protein concentration using the BCA method. Proteins at a concentration of 100 g/L were analyzed with SDS-PAGE before membrane transfer and mounting. Primary and secondary antibodies (diluted at 1:1,000) were added for incubation. The cultures were analyzed by using enhanced chemiluminescence, and the optical densities (ODs) were determined by using
LabWorks 4.0. The protein expressions were represented by the ratio of the corresponding OD to the GAPDH.

Dual-luciferase reporter assay

The primary BSMC culture was performed in a routine fashion by using an incubator at 37 °C with 5% CO₂. The primary BSMCs were harvested in the exponential phase of growth and inoculated into a 96-well culture plate at a density of 1.5 ×10⁴ cells per well, where each well had a capacity of 100 μL, and were cultured for 24 h. Following this, the miRNA mimics, their negative controls, and the reporter gene vector of the target mRNA 3’UTR Lipofectamine 2000 were diluted in respective media and mixed thoroughly. After letting them stand for 20 min, the solutions were added to the cells, respectively. Experiments were performed in triplicates. The substrates were added 48 h after transfection to determine the fluorescent intensity.

Statistical analysis

The software SPSS 22.0 was used for data analysis. The measurement data are labeled as “mean ± standard deviation (mean ± SD).” The intergroup comparison was examined by the t-test (two groups) or by ANOVA (three or more groups), with the results considered to be significant if P<0.05.

Results

Primary BSMC identification and construction of PBOO cell model
α-SMA is a marker protein of BSMCs. Once the BSMCs had been extracted, the cell immunofluorescence assay revealed both the cellular morphology and the α-SMA expression were consistent with BSMC criteria (Fig. 1A). TGF-β1 was used to stimulate the BSMCs and construct an in-vitro cell model of PBOO. When stimulated with TGF-β1 at different concentrations, the rate of cell proliferation and level of expression of F-actin significantly increased compared with those of the TGF-β1 (0 mg/ml) group (P<0.001, Figs. 1B and 1C), and the dose–effect relation was identified by using the TGF-β1 concentration (P<0.05, Figs. 1B and 1C).

Expression levels of α-SM-actin and SM22α upon TGF-β1 stimulation at various concentrations

The cell immunofluorescence assay indicated that compared with the TGF-β1 (0 mg/ml) group, the groups stimulated with TGF-β1 showed significant differences in the levels of expression of α-SM-actin and SM22α (P<0.05, Figs. 2A and 2B), and exhibited a significant dose–effect relation with TGF-β1 (P<0.05, respectively, Figs. 2A and 2B).

Expressions of ILK, TLR4, MyD88, and NF-κB(p65) proteins detected

Compared with the TGF-β1 (0 mg/ml) group, TGF-β1 intervention raised the levels of expression of the ILK, TLR4, MyD88, and NF-κB(p65) (P<0.05, Figs. 3A–3D, respectively), and the dose–effect relationship with TGF-β1 concentration was detected (P<0.05, Figs. 3A–3D, respectively).
Expressions of myocardin and SRF proteins

Compared with the TGF-β1 (0 mg/ml) group, TGF-β1 intervention raised the levels of expression of myocardin and SRF proteins (P<0.05, Figs. 4A and 4B, respectively), and a dose–effect relationship with TGF-β1 concentration was detected (P<0.05, Figs. 4A and 4B, respectively).

Relative gene and protein expressions

The results of RT-qPCR assay showed that compared with the TGF-β1 (0 mg/ml) group, expressions of ILK, TLR4, MyD88, NF-κB(p65), myocardin, and SRF genes and proteins were significantly up-regulated, and that of miRNA-325-3p was significantly down-regulated in the TGF-β1-treated groups in a dose-dependent manner (P<0.05, Figs. 5A and 5B, respectively).

Cell proliferation and F-actin expression in different groups

The results of CCK-8 assay showed that the rate of proliferation of the TGF-β1 group was significantly higher than that of the blank group, (P<0.001, Fig. 6A). In case miRNA-325-3p was supplemented, the rate of proliferation of the TGF-β1+miRNA-325-3p group was significantly reduced compared with that of the TGF-β1 group (P<0.001, Fig. 6A). With ILK transfection, the rate of proliferation of the TGF-β1+miRNA-325-3p+LV-ILK group significantly increased compared with that of the TGF-β1+miRNA-325-3p group (P<0.001, Fig. 6A). With cellular immunofluorescence,
the F-actin protein expression of the TGF-β1 group increased significantly compared with that of the blank group (P<0.001, Fig. 6B). When miRNA-325-3p was supplemented, the F-actin protein expression of the TGF-β1+miRNA-325-3p group was significantly reduced compared with the TGF-β1 group (P<0.001, Fig. 6B). With ILK transfection, the F-actin protein expression of the TGF-β1+miRNA-325-3p+LV-ILK group increased significantly compared with the TGF-β1+miRNA-325-3p group (P<0.001, Fig. 6B).

α-SM-actin and SM-22α protein expressions

Cellular immunofluorescence significantly increased the expression of α-SM-actin and significantly reduced that of SM-22α compared with those of the blank group (P<0.001, Figs. 7A and 7B). The supplementation of miRNA-325-3p significantly reduced the expression of α-SM-actin and significantly increased that of SM-22α compared with values of the TGF-β1 group (P<0.001, Figs. 7A and 7B). ILK transfection significantly increased the expression of α-SM-actin while significantly reducing that of SM-22α compared with those of the TGF-β1+miRNA-325-3p group (P<0.001, Fig. 7A and 7B).

ILK, TLR 4, MyD88, and NF-κB(p65) protein expressions

Cellular immunofluorescence significantly increased the expressions of ILK, TLR 4, MyD88, and NF-κB(p65) proteins in the TGF-β1 group compared with those of the compared blank group (P<0.001, respectively, Fig. 8). The miRNA-325-3p supplement
significantly reduced expressions of ILK, TLR 4, MyD88, and NF-κB(p65) proteins in the TGF-β1+miRNA-325-3p group compared with the TGF-β1 group (P<0.001, Fig. 8). ILK transfection significantly increased expressions of the ILK, TLR 4, MyD88, and NF-κB(p65) proteins in the TGF-β1+miRNA-325-3p+LV-ILK group compared with compared with the TGF-β1+miRNA-325-3p group (P<0.001, Fig. 8).

Expressions of myocardin and SRF proteins

Cellular immunofluorescence significantly increased expressions of myocardin and SRF proteins in the TGF-β1 group compared with compared the blank group (P<0.001, Figs. 9A and 9B, respectively). The miRNA-325-3p supplement significantly reduced expressions of myocardin and SRF proteins in the TGF-β1+miRNA-325-3p group compared with the TGF-β1 group (P<0.001, Figs. 9A and 9B, respectively). ILK transfection significantly increased expressions of myocardin and SRF proteins in the TGF-β1+miRNA-325-3p+LV-ILK group compared with the TGF-β1+miRNA-325-3p group (P<0.001, Figs. 9A and 9B, respectively).

Relative gene and protein expressions

The results of RT-qPCR assay show that the mRNA expression of miRNA-325-3p had been significantly down-regulated in the TGF-β1 group compared with the blank group (P<0.001, Fig. 10). Compared with the TGF-β1 group, the expressions of miRNA-325-3p of the TGF-β1+miRNA-325-3p and TGF-β1+miRNA-325-3p+LV-ILK groups had been significantly up-regulated (P<0.001, respectively, Figs. 10A and
10B). Compared with Blank group, ILK, TLR 4, MyD88, NF-κB(p65), myocardin, and SRF gene and proteins expression were significantly up-regulated in TGF-β1 group (P<0.001, Figs. 10A and 10B, respectively). miRNA-325-3p transfection had significantly down-regulated ILK, TLR 4, MyD88, NF-κB(p65), myocardin, and SRF gene and proteins expressions in the TGF-β1+miRNA-325-3p group compared with the TGF-β1 group (P<0.001, Figs. 10A and 10B, respectively). The ILK supplement had significantly up-regulated expressions of ILK, TLR 4, MyD88, NF-κB(p65), myocardin, and SRF genes and proteins in the TGF-β1+miRNA-325-3p+LV-ILK group compared with the TGF-β1+miRNA-325-3p group (P<0.001, Figs. 10A and 10B, respectively).

Correlation between miRNA-325-3p and ILK

In Mul group, no significant differences were observed between the miRNA-NC and the miRNA-325-3p groups (P>0.05, Fig. 11). In WT groups the relative luciferase was significantly reduced in the miRNA-325-3p group compared with that of the miRNA-NC group (P<0.001, Fig. 11).

Discussion

PBOO refers to a class of conditions manifested by difficulties in urination caused by increased obstruction to urinary flow due to anomalies in the bladder neck and/or the urethra[15]. In this study, a model of rats with PBOO was established to investigate pathological changes and the degree of fibrosis in it. The results showed that the
homeostasis between the apoptosis and proliferation of the SMC at the outlet of the bladder had been disrupted, and a significantly higher degree of fibrosis was detected. This suggests that BSMC hyperproliferation-induced fibrosis may serve as a major contributor to PBOO.

The BSMCs were shown to have undergone a series of adaptations in response to harmful stimulation, including hypertrophy, phenotypic plasticity, proliferation, apoptosis, and, ultimately, the functional decompensation of the bladder. When PBOO occurs, lowered expression of contractile proteins has been reported to result from reversible phenotypic plasticity in the damaged BSMCs and transformation in the corresponding genes, leading to significant proliferation and contractile dysfunction in the BSMCs [16]. PBOO-induced vasoactive substance production by local inflammatory cells in the bladder, such as transforming growth factor beta 1 (TGF-β1), basic fibroblast growth factor (bFGF), and heparin-binding epidermal growth factor (HB-EGF), can stimulate BSMC proliferation [17]. Luo et al. [18] provided further evidence for the presence of phenotypic plasticity in human and rat BSMCs, as well as resultant bladder fibrosis caused by subsequent changes in BSMC proliferation and ECM secretion. Therefore, PBOO-induced BSMC phenotypic plasticity is considered to be an initial event, followed by changes in BSMC proliferation and migration. In this study, an in-vitro PBOO model was constructed by using TGF-β1 to stimulate primary BSMCs, and the results revealed a significant increase in the rate of BSMC proliferation as well as a markedly higher degree of fibrosis. Moreover, miR-325-3p gene expression was significantly reduced.
The miRNA family is a large group of small non-coding RNAs, with lengths ranging from 19 to 22 nt and the shared function of regulating target mRNA levels through imperfect binding to specific sites within the 3’UTR region of mRNA sequences. Moreover, miRNAs are known to regulate epigenetic inheritance and modification, including DNA methylation, RNA modification, and histone modification [19]. The imperfect complementarity between miRNAs and their targets determines the intricacy of the miRNA–miRNA interaction. Although miRNA expression is relatively low in normal physiological conditions, it plays a vital role in the maintenance of normal physiological function of the bladder detrusor muscle. Studies evaluating miRNAs in the bladder detrusor muscle [20, 21] have reported that in Dicer-knockout mouse models, miRNA exhaustion occurs in the bladder detrusor muscle after 10 weeks of observation, in which case voiding dysfunction, frequent urination, and reduced anticholinergic properties are observed. miRNA disorders can also lead to bladder dysfunction, including bladder pain syndrome [22, 23], inflammation-induced hyperactivity [21], and responses to outlet obstruction (in both animal and human studies) [7, 10, 12, 21, 24]. Further, miRNAs are known to have regulatory effects on specific cell phenotypes in the urinary tract, such as stimulating BSMC proliferation and modulating uroepithelial permeability [23]. In this study, a PBOO model was established by using TGF-β1 and primary BSMCs, where cell proliferation and fibrosis were found to have accelerated significantly and miR-325-3p gene expression was noted to have decreased remarkably. The transfection of miR-325-3p into primary BSMCs was shown to efficiently inhibit TGF-β1-induced
hyperproliferation and the resultant fibrosis. A gene assay of the dual-luciferase reporter suggested that ILK is a target of miR-325-3p.

ILK is a multifunctional protein with a molecular mass of 59 kD that was first described by Hannigan in a study on integrin β1 binding proteins in 1996. It has also been identified as a serine/threonine protein kinase involved in integrin-mediated signal transduction that is expressed in a wide range of mammal cells [12]. ILK is involved in a diversity of physiological functions as its kinase domain interacts with integrin β subunit cytoplasmic tails and extracellular integrin domains connected to the extracellular matrix. Wu et al. studied the role of ILK in the phenotypic plasticity of SMCs, and discovered a negative correlation between ILK and RhoA/ROCK activity in the gene expression of phenotypic plasticity markers of SMCs as well as a supportive role of ILK in the maintenance of the contractile phenotype of SMCs [26-28]. The results of this study suggest that transfection of BSMCs with miR-325-3p can reduce the ILK expression, thus further inhibiting TGF-β1-mediated BSMC hyperproliferation and fibrosis. In addition, the TLR4/MyD88/NF-κB(p65) signaling pathway was strongly inhibited in this way.

The activated TLR4/MyD88/NF-κB(p65) signaling pathway has been reported to play an important role in the development of inflammation and fibrosis [29-31], and it has been proposed that it is regulated by ILK [32]. Moreover, it has recently been discovered that the TLR4/MyD88/NF-κB(p65) signaling pathway can regulate expressions of the serum response factor (SRF) and myocardin [33]. The most effective known SRF coactivator myocardin discovered by Eric Olson’s laboratory is able to
activate SMC phenotypic plasticity, as well as a series of SRF-regulated transcription of gene encoding cytoskeletal proteins and contractile associated proteins [33, 34]. The results of this study showed that increased ILK expression upon TGF-β1’s stimulation can activate the TLR4/MyD88/NF-κB(p65) signaling pathway, substantially alter the gene and protein expressions in the downstream SRF and myocardin, and promote BSMC proliferation and fibrosis. However, the TGF-β1-mediated BSMC hyperproliferation and fibrosis were inhibited following the transfection of miR-325-3p into the BSMCs, where this also reduced the ILK expression, lowered the activity of the TLR4/MyD88/NF-κB(p65) signaling pathway and inhibited the gene and protein expressions in the downstream SRF and myocardin.

In conclusion, miR-325-3p inhibits the activation of the TLR4/MyD88/NF-κB(p65) signaling pathway by regulating the ILK expression to reduce BSMC hyperproliferation and fibrosis in the PBOO model.

References:
biochemistry, and pharmacology 2017; 44:907-919.


13. Shi-Pin Wu, Zhi Yang, Fu-Rong Li, Xiao-Di Liu, Hong-Tao Chen, Dong-Na Su. Smad7-overexpressing rat BMSCs inhibit the fibrosis of hepatic stellate cells by regulating the TGF-β1/Smad signaling pathway. Exp Ther Med. 2017 Sep; 14(3):2568-2576.


28. Mitra Shafieian, Shaoyi Chen, Shu Wu. Integrin-linked kinase mediates CTGF-


Figure legends

Figure 1. Primary BSMC cell identification and PBOO cell model construction

A. α-SMA protein by immunofluorescence assay (200×)

B. Proliferation rate of difference groups

C. F-actin protein expression of difference groups by immunofluorescence assay
Figure 2. Expression levels of α-SM-actin and SM22α upon TGF-β1 at various concentrations

A. α-SM-actin protein expression of difference groups (200×)

B. SM-22α protein expression of difference groups (200×)

*: P<0.05, **: P<0.01, ***: P<0.001, compared with TGF-β1(0 ng/ml); #: P<0.05, ##: P<0.01, compared with TGF-β1(1 ng/ml); &: P<0.05, compared with TGF-β1(5 ng/ml)

Figure 3. Expression of ILK, TLR4, MyD88 and NF-κB(p65) proteins detected with cell immunofluorescence assay

A. ILK protein expression of difference groups (200×)

B. TLR4 protein expression of difference groups (200×)

C. MyD88 protein expression of difference groups (200×)

D. NF-κB(p65) protein expression of difference groups (200×)

*: P<0.05, **: P<0.01, ***: P<0.001, compared with TGF-β1(0 ng/ml); #: P<0.05, ##: P<0.01, compared with TGF-β1(1 ng/ml); &: P<0.05, compared with TGF-β1(5 ng/ml)

Figure 4. Expression of Myocardin and SRF proteins as detected with cell immunofluorescence

A. Myocardin protein expression of difference groups (200×)

B. SRF protein expression of difference groups (200×)

*: P<0.05, **: P<0.01, ***: P<0.001, compared with TGF-β1(0 ng/ml); #: P<0.05, ##: P<0.01, compared with TGF-β1(1 ng/ml); &: P<0.05, compared with TGF-β1(5 ng/ml)
Figure 5. Differences in the expression of ILK, TLR4, MyD88, NF-κB(p65), Myocardin and SRF
A. Relative mRNA expression in difference groups
B. Relative proteins expression in difference groups
*: P < 0.05, **: P < 0.01, ***: P < 0.001, compared with TGF-β1 (0 ng/ml); #: P < 0.05, ##: P < 0.01, compared with TGF-β1 (1 ng/ml; &: P < 0.05, compared with TGF-β1 (5 ng/ml)

Figure 6. Cell proliferation and F-actin expression in difference groups
Blank: The BSMC cell treated with normal; miRNA-NC: The BSMC were transfected with miRNA-negative control (NC); LV-NC: The BSMC were transfected with LV-negative control (NC); TGF-β1: The BSMC were treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p: The BSMC transfected with miRNA-325-3p and treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p+LV-ILK: The BSMC transfected with miRNA-325-3p and ILK and treated with 10ng/ml TGF-β1
A. Proliferation rate of difference groups
B. F-actin protein expression of difference groups (200×)
***: P < 0.001, compared with Blank group; ###: P < 0.001, compared with TGF-β1 group; @@@: P < 0.001, compared with TGF-β1+miRNA-325-3p group

Figure 7. α-SM-actin and SM-22α protein expression by cellular immunofluorescence
Blank: The BSMC cell treated with normal; miRNA-NC: The BSMC were transfected with miRNA-negative control (NC); LV-NC: The BSMC were transfected with LV-negative control (NC); TGF-β1: The BSMC were treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p: The BSMC transfected with miRNA-325-3p and treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p+LV-ILK: The BSMC transfected with miRNA-325-3p and ILK and treated with 10ng/ml TGF-β1
A. α-SM-actin protein expression (200×)
B. SM-22α protein expression (200×)
***: P < 0.001, compared with Blank group; ###: P < 0.001, compared with TGF-β1 group; @@@: P < 0.001, compared with TGF-β1+miRNA-325-3p group

Figure 8. Relative proteins expression by cellular immunofluorescence
Blank: The BSMC cell treated with normal; miRNA-NC: The BSMC were transfected with miRNA-negative control (NC); LV-NC: The BSMC were transfected with LV-negative control (NC); TGF-β1: The BSMC were treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p: The BSMC transfected with miRNA-325-3p and treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p+LV-ILK: The BSMC transfected with miRNA-325-3p and ILK and treated with 10ng/ml TGF-β1
A. ILK protein expression (200×)
B. TLR 4 protein expression (200×)
C. MyD88 protein expression (200×)
D. NF-κB(p65) protein expression (200×)
***: P < 0.001, compared with Blank group; ###: P < 0.001, compared with TGF-β1 group; @@@: P < 0.001, compared with TGF-β1+miRNA-325-3p group

Figure 9. Myocardin and SRF protein expression
Blank: The BSMC cell treated with normal; miRNA-NC: The BSMC were transfected with miRNA-negative control (NC); LV-NC: The BSMC were transfected with LV-negative control (NC); TGF-β1: The BSMC were treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p: The BSMC transfected with miRNA-325-3p and treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p+LV-ILK: The BSMC transfected with miRNA-325-3p and ILK and treated with 10ng/ml TGF-β1
A. Myocardin protein expression (200×)
B. SRF protein expression (200×)
***: P < 0.001, compared with Blank group; ###: P < 0.001, compared with TGF-β1 group; @@@: P < 0.001, compared with TGF-β1+miRNA-325-3p group

Figure 10. Relative gene and protein expression
Blank: The BSMC cell treated with normal; miRNA-NC: The BSMC were transfected with miRNA-negative control (NC); LV-NC: The BSMC were transfected with LV-negative control (NC); TGF-β1: The BSMC were treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p: The BSMC transfected with miRNA-325-3p and treated with 10ng/ml TGF-β1; TGF-β1+miRNA-325-3p+LV-ILK: The BSMC transfected with miRNA-325-3p and ILK and treated with 10ng/ml TGF-β1

A. Relative gene expression
B. Relative protein expression

***: P<0.001, compared with Blank group; ###: P<0.001, compared with TGF-β1 group; @@@: P<0.001, compared with TGF-β1+miRNA-325-3p group

Figure 11. Correlation between miRNA-325-3p and ILK

***: P<0.001, compared with miRNA-NC
<table>
<thead>
<tr>
<th>Gene Name</th>
<th>F:(5’-3’)</th>
<th>R:(5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILK</td>
<td>TTCGTTGTGGACCAGAGCCAAG</td>
<td>AGTGCGTGCCAGGATGAGA</td>
</tr>
<tr>
<td>TLR4</td>
<td>TCCAGAGCGTTGGGTATCTT</td>
<td>ACAATTGCACCTGCTGCCCTCA</td>
</tr>
<tr>
<td>MyD88</td>
<td>CGTCGCATGGTGTTGGTTGTT</td>
<td>TCGCTTCTTGACACCTGGGA</td>
</tr>
<tr>
<td>NF-κB(p65)</td>
<td>TGTGGTGAGGGACTTGGCTGAGG</td>
<td>GGAGTGCTGCTTGGCTTGTCTT</td>
</tr>
<tr>
<td>Myocardin</td>
<td>CAAGGGTGTCGACAGATGAC</td>
<td>TAGGATGGGGGCTGGGTAT</td>
</tr>
<tr>
<td>SRF</td>
<td>CATGACGTCGCTGTACCCCA</td>
<td>GAGGTGGGGGCAATACAC</td>
</tr>
<tr>
<td>miRNA-325-3p</td>
<td>CGCGCCTAGTAGGGTGCTCGAGT</td>
<td>AGTGCAAGGTCCAGGTATT</td>
</tr>
<tr>
<td>U6</td>
<td>CTCGCTCCGGCCAGCACA</td>
<td>TGTTGCTGGAGTGC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>CGGCAAGTTCAACGGCACAGT</td>
<td>CGCTCCTGGAAGATGGTAGTGG</td>
</tr>
</tbody>
</table>